Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 25, 2017
Event: Entry into a Material Definitive Agreement with Otsuka Pharmaceutical Co. Ltd. regarding the development and commercialization of vadadustat, an oral hypoxia-inducible factor (HIF) stabilizer for anemia related to chronic kidney disease.
Key Financial Metrics and Deal Terms
This filing details a strategic collaboration rather than standard periodic financial results. Key financial terms of the agreement include:
- Upfront Payment: $73 million payable upon execution.
- Development Funding: At least $135 million from Otsuka.
- Total Minimum Expected Payment: At least $208 million.
- Milestone Payments: Up to $657 million in aggregate development and commercial milestones.
- Royalties: Tiered, escalating payments ranging from low double digits to 30% of net sales within the Territory.
- Territory: European Union, Russia, China, Australia, Canada, the Middle East, and certain other countries (excludes Latin America and previously licensed countries).
Note: The filing does not provide current revenue, profit, cash flow, or debt figures for the company.
Material Changes and Operational Impact
This agreement expands upon a prior collaboration dated December 18, 2016, which covered the United States. Under the new terms:
- Otsuka assumes responsibility for development activities and commercialization in the defined Territory.
- Akebia retains leadership of the global Phase 3 development program.
- Otsuka will fund a significant percentage of the global development program costs regardless of actual costs incurred.
- Akebia retains final decision-making authority regarding manufacture, supply, global Phase 3 development, and global brand strategy.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing includes expectations regarding Otsuka's funding obligations and potential commercialization, subject to regulatory approval.
Key Risks and Contingencies:
- Failure to achieve development or commercial milestones.
- Uncertainty in successfully completing clinical development.
- Potential for actual development costs to exceed current anticipations.
- Availability of financing to cover costs not funded by Otsuka.
- Regulatory delays or unfavorable decisions.
- Capital constraints affecting clinical program timelines.
- Intellectual property protection challenges.
Termination: Otsuka may terminate the agreement for a sub-territory or in its entirety with 12 months' prior written notice after the release of the first topline data in the global Phase 3 program.
Investor Verification Checklist
- Verify the receipt of the $73 million upfront payment and its impact on the company's cash position.
- Confirm the specific milestones triggering the $657 million in potential payments.
- Monitor the progress of the global Phase 3 development program for vadadustat.
- Review the upcoming Form 10-Q for the quarter ending June 30, 2017, for the full text of the Agreement.
- Assess the company's remaining cash runway and funding needs outside of Otsuka's contributions.